Revvity, Inc.
About Revvity, Inc.
Company overview
Revvity is a global company that excels in providing innovative solutions and technologies to enable better health and safety outcomes across various industries. The company's mission is to improve human and environmental health through its cutting-edge products and services, which span a wide range of applications, including life sciences, diagnostics, environmental monitoring, food safety, and industrial testing. Product Breakdown: Revvity offers an extensive portfolio of products and solutions designed to address critical challenges and drive advancements in various domains. Life Sciences and Diagnostics: Genomics: Revvity provides advanced genomic analysis tools, including DNA sequencers, microarray platforms, and associated software, empowering researchers to study genetic variations and gain insights into diseases and human health. Drug Discovery and Development: The company offers a broad range of solutions for drug discovery, such as high-throughput screening systems, imaging technologies, and informatics software to accelerate the development of novel pharmaceuticals. In Vitro Diagnostics (IVD): Revvity's IVD solutions include diagnostic kits, reagents, and instrumentation for clinical laboratories, aiding in the detection and monitoring of various diseases, including cancer, infectious diseases, and genetic disorders. Environmental Health: Environmental Monitoring: Revvity delivers advanced instruments and software for monitoring and analyzing environmental pollutants, ensuring compliance with regulatory standards and supporting environmental research. Industrial Hygiene and Safety: The company offers solutions for workplace safety and industrial hygiene, including gas analyzers, radiation detectors, and personal protective equipment (PPE), safeguarding workers from occupational hazards. Food and Beverage Safety: Food Testing Solutions: Revvity's food testing instruments and services enable the detection of contaminants, allergens, and adulterants in food products, ensuring food safety and quality. Beverage Testing Solutions: The company provides analytical instruments to assess the quality and authenticity of beverages, including alcoholic beverages, juices, and water. Informatics and Software: Revvity offers a range of informatics and software solutions to support data management, analysis, and collaboration for scientific research and laboratory operations. Laboratory Services: In addition to its product offerings, Revvity offers laboratory services, including analytical testing, genomics services, and consulting, assisting customers in achieving their scientific and business objectives. Revvity's products are widely used across academic and research institutions, healthcare facilities, pharmaceutical and biotechnology companies, industrial laboratories, and government organizations. The company's commitment to innovation, quality, and customer satisfaction has earned it a reputation as a leading provider of solutions that positively impact human health and the environment.
Keywords
Revenue
EBITDA
Valuation
| Line Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenues | $380 MM | $250 MM | $90 MM | $120 MM | $65 MM |
| Gross Profit | $190 MM | $125 MM | $45 MM | $60 MM | $32.50 MM |
| Net Income (Loss) | $43 MM | $25 MM | $9 MM | $12 MM | $6.50 MM |
| Line Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $850 MM | $720 MM | $680 MM | $650 MM | $600 MM |
| Total Liabilities | $450 MM | $400 MM | $380 MM | $350 MM | $320 MM |
| Total Equity | $400 MM | $320 MM | $300 MM | $300 MM | $280 MM |
Ratios
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
© 2026 PrivCo Holding Inc. All rights reserved.
No AI Training or Automated Data Extraction.
Use of this page or any content or data made available by PrivCo for scraping, crawling, indexing, caching, extracting, copying, reproducing, storing, or for training or developing any artificial intelligence or machine learning system is strictly prohibited without prior written consent. All access to and use of this page and PrivCo's services are subject to the PrivCo Terms of Use: https://www.privco.com/terms-of-use. No license or right is granted by implication or otherwise.